3D imaging and artificial intelligence to predict cancer therapy effectiveness

Elephas Biosciences Corporation is pioneering an advanced imaging platform designed to predict patient responses to immunotherapy by utilizing live patient biopsies. This innovative platform preserves the native tumor microenvironment, allowing for the assessment of how tumors react to various immunotherapies. By visualizing immune cell activity, including T cell activation and cytotoxic responses, Elephas aims to establish a correlation between the data generated from their platform and the clinical responses observed in patients undergoing immunotherapy. This approach is particularly significant given the challenges in accurately predicting which patients will benefit from available treatments.

The company is actively collaborating with the Mayo Clinic to enhance the development of its oncology imaging diagnostics platform. This partnership focuses on validating the platform's capabilities and advancing translational research efforts. Elephas' proprietary instruments play a crucial role in this diagnostic process, enabling rapid and real-time characterization of tumor responses. As cancer continues to be a leading cause of mortality worldwide, Elephas is committed to addressing the critical need for accurate predictive biomarkers, thereby improving treatment outcomes for patients battling cancer.

United States

Elephas is a biopharmaceutical company focused on developing an oncology imaging diagnostics platform to predict response to immunotherapy using the latest advances in metabolic and ex-vivo technology. The company is also building an instrument platform that will inform how clinicians treat cancer patients by interrogating live human tumors ex vivo.

Elephas

Company Details